Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wan, Hongquan ^a   Yang, Hua ^b   Shore, David A ^b   Garten, Rebecca J ^b   Couzens, Laura ^a   Gao, Jin ^a   Jiang, Lianlian ^a   Carney, Paul J ^b   Villanueva, Julie ^b   Stevens, James ^b   Eichelberger, Maryna C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G2A; MONOMER; VIRUS SIALIDASE; AMINO ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN BINDING; SIALIDASE; VIRUS ANTIBODY; VIRUS ANTIGEN;

AMINO ACID; ANTIBODY; DRUG DEVELOPMENT; FOOD AND AGRICULTURAL ORGANIZATION; INFLUENZA; PROTEIN; RODENT; VIRUS;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROGEN BOND; INFLUENZA A (H1N1); INFLUENZA A VIRUS; MOLECULAR CLOCK; MOUSE; NONHUMAN; PLAQUE ASSAY; POINT MUTATION; PROTEIN QUATERNARY STRUCTURE; SITE DIRECTED MUTAGENESIS; STEREOSPECIFICITY; SURVIVAL; VIRUS ATTACHMENT; WEIGHT REDUCTION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DBA MOUSE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYMOLOGY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); METABOLISM; MOLECULAR GENETICS; ORTHOMYXOVIRUS INFECTION; STRUCTURE ACTIVITY RELATION; VIROLOGY;

UNITED STATES;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; EPITOPES; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84939428578     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7114     Document Type: Article

References (53)

1. CDC. Update: influenza activity - United States, September 29, 2013-February 8, 2014. MMWR 63, 148-154 (2014).
2. CDC. FluVaxView. Centers for Disease Control and Prevention http://www.cdc.gov/flu/fluvaxview/1314season.htm (2014).
3. Moscona, A. Neuraminidase inhibitors for influenza. New Engl. J. Med. 353, 1363-1373 (2005).
4. Memoli, M. J. et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 203, 348-357 (2011).
5. Sheu, T. G. et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52, 3284-3292 (2008).
6. WHO. Recommended Composition of Influenza Virus Vaccines for Use in the 2014-15 Northern Hemisphere Influenza Season (World Health Organization, 2014) http://www.who.int/influenza/vaccines/virus/recommendations/2014-15-north/en/.
7. Hayden, F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl 1): S3-S13 (2009).
8. Connaris, H. et al. Prevention of influenza by targeting host receptors using engineered proteins. Proc. Natl Acad. Sci. USA 111, 6401-6406 (2014).
9. Hung, I. F. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144, 464-473 (2013).
10. Kreil, T. R. et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion 52, 803-809 (2012).
11. Gordon, C. L. et al. Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin. Infect. Dis. 52, 422-426 (2011).
12. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
13. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
14. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
15. Wan, H. et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J. Virol. 87, 9290-9300 (2013).
16. Doyle, T. M. et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 100, 567-574 (2013).
17. Doyle, T. M. et al. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem. Biophys. Res. Commun. 441, 226-229 (2013).
18. Shoji, Y. et al. An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses. Hum. Vaccin. 7(Suppl): 199-204 (2011).
19. Li, Q. et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 17, 1266-1268 (2010).
20. Amaro, R. E. et al. Mechanism of 150-cavity formation in influenza neuraminidase. Nat. Commun. 2, 388 (2011).
21. van der Vries, E. et al. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog. 8, e1002914 (2012).
22. Tulip, W. R., Varghese, J. N., Laver, W. G., Webster, R. G. & Colman, P. M. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 227, 122-148 (1992).
23. Malby, R. L. et al. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 2, 733-746 (1994).
24. Venkatramani, L. et al. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J. Mol. Biol. 356, 651-663 (2006).
25. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
26. Storms, A. D. et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis. 18, 308-311 (2012).
27. Memoli, M. J., Hrabal, R. J., Hassantoufighi, A., Eichelberger, M. C. & Taubenberger, J. K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 50, 1252-1255 (2010).
28. Gulati, U. et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J. Virol. 76, 12274-12280 (2002).
29. Colman, P. M. et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 326, 358-363 (1987).
30. Lee, J. T. & Air, G. M. Contacts between influenza virus N9 neuraminidase and monoclonal antibody NC10. Virology 300, 255-268 (2002).
31. Saito, T., Taylor, G., Laver, W. G., Kawaoka, Y. & Webster, R. G. Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J. Virol. 68, 1790-1796 (1994).
32. Barbey-Martin, C. et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 294, 70-74 (2002).
33. Iba, Y. et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J. Virol. 88, 7130-44 (2014).
34. Air, G. M., Els, M. C., Brown, L. E., Laver, W. G. & Webster, R. G. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 145, 237-248 (1985).
35. Webster, R. G. et al. Antigenic structure and variation in an influenza virus N9 neuraminidase. J. Virol. 61, 2910-2916 (1987).
36. Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39-44 (2012).
37. Tong, S. et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 9, e1003657 (2013).
38. Xu, X., Zhu, X., Dwek, R., Stevens, J. & Wilson, I. Structural characterization of the 1918 influenza H1N1 neuraminidase. J. Virol. 82, 10493-10501 (2008).
39. Otwinowski, Z. & Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods in Enzymology 276, 307-326 (1997).
40. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. Likelihood-enhanced fast translation functions. Acta. Crystallogr. D Biol. Crystallogr. 61, 458-464 (2005).
41. Mylvaganam, S. E., Paterson, Y. & Getzoff, E. D. Structural basis for the binding of an anti-cytochrome c antibody to its antigen: crystal structures of FabE8-cytochrome c complex to 1.8 A resolution and FabE8 to 2.26 A resolution. J. Mol. Biol. 281, 301-322 (1998).
42. Zhu, X., Tanaka, F., Lerner, R. A., Barbas, 3rd C. F. & Wilson, I. A. Direct observation of an enamine intermediate in amine catalysis. J. Am. Chem. Soc. 131, 18206-18207 (2009).
43. CCP4. The CCP4 suite: programs for protein crystallography. Acta. Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
44. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
45. Winn, M. D., Isupov, M. N. & Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta. Crystallogr. D Biol. Crystallogr. 57, 122-133 (2001).
46. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
47. Couzens, L. et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J. Virol. Methods 210C, 7-14 (2014).
48. Gerhard, W. & Webster, R. G. Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies. J. Exp. Med. 148, 383-392 (1978).
49. Hoffmann, E., Stech, J., Guan, Y., Webster, R. G. & Perez, D. R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146, 2275-2289 (2001).
50. Katoh, K., Asimenos, G. & Toh, H. Multiple alignment of DNA sequences with MAFFT. Methods Mol. Biol. 537, 39-64 (2009).
51. Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-2739 (2011).
52. Drummond, A. J., Suchard, M. A., Xie, D. & Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29, 1969-1973 (2012).
53. Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503-W508 (2008).